Early Career Investigator Symposium

The Division sponsors the Early Career Investigator Symposium (formerly known as the Young Investigator Symposium) annually at the Fall ACS meeting. Appropriate candidates will be independent investigators who are no more than 10 years from graduate school or post-doctoral appointment, be a current researcher in a non-academic setting (e.g. industry, government or non-profit laboratory) and have demonstrated outstanding promise for future contributions to Organic Chemistry. A nomination letter should be written by the head of a department or division, and should highlight the scientist’s promise, creativity, and productivity. Importantly, please also address the nominee’s ability to present a 30 minute scientific talk at the Fall ACS meeting that contains a substantial amount of the scientist’s own work, along with a very brief description of the talk’s topic. A copy of the candidate’s CV should also be included. We understand that certain settings may not encourage frequent publications, and accordingly, publication record will not be a primary criterion for an invitation to speak. Our goal is to put together a symposium of young, up-and-coming scientists from a range of backgrounds, organizations and industries.

Nominations for the 2022 Early Career Symposium are due February 11, 2022. The symposium honoring the selected candidates will take place at the Fall 2022 ACS National Meeting. Send nominations to Drs. Lisa Marcaurelle and Steve Silverman.

Nominations from women and minorities who are typically under-represented in chemistry are especially encouraged. Thanks for your support of this program, and for your willingness to help develop young scientists by providing them with opportunities to speak at a national meeting and to interact with other scientists. If you have any questions, please do not hesitate to contact us .


2021 Young Investigator’s Symposium

Omar Ahmad, Blueprint

Christophe Allais, Pfizer

Matthew Beaver, Amgen

Raphaelle Berger, Merck

Alexander Buitrago-Santanilla, GSK

Ida Chen, Dow

Anne-Marie Dechert Schmitt, Pfizer

Amelie Dion, Merck/Pfizer

Anna Dunn, GSK

Candice Joe, BMS

Anais Jolit, AbbVie

Leo Joyce, Arrowhead

Carolyn Leverett, Pfizer

Xiaoli Liao, AbbVie

Brian Loy, Corteva Agriscience

Yu Lu, Lilly

Feng Peng, Merck

Vivek Rauniyar, Novartis

Chris Regens, Gilead

Troy Reynolds, AbbVie

Trevor Sherwood, BMS

Steven Silverman, Merck

Lauren Sirois, Genentech

Craig Stivala, Genentech

Shun Su, BMS

Benjamin Taft, Novartis

Dan Treitler, BMS

Tom Willumstad, Dow

Yun Zhang, AstraZeneca

2020 Young Investigator’s Symposium

Matthew Belowich, Dow

Tamas Benkovics, Merck

J Robb Debergh, FMC – DuPont

Nick Desrosiers, Pfizer

Anna Fryszkowska, Merck

Natalie Giampietro, Corteva-Dow

Chong Han, Genentech

Seb Monfette, Pfizer

Ryan Moslin, BMS

Jaclyn Murphy, DuPont

Zack Oblak, GSK

Martins Oderinde, BMS

Andrew Parsons, Amgen

Ryan Patman, Pfizer

David Pearson, Dow

Christopher Plummer, Merck

Danica Rankic, Pfizer

Mari Rosen, Dow

Janelle Steves, GSK

Aimee Usera, Novartis

Jason Zbieg, Genentech

2019 Young Investigator’s Symposium

Brad Bailey, Dow
Polyolefin catalysts for the production of ethylene-based fluids

Bryan Barton, Dow Dupont E&I
Shifting the oxidation pathways of polyethylene to provide carbonaceous species in high yield

Amanda Dombrowski, Abbvie
High-throughput reaction screening enabled by small scale solid dispensing

Shuzhi Dong, Merck
Discovery of MK-8153: ROMK inhibitor as new mechanism diuretic for hypertension and heart failure

Stephen Greszler, Abbvie
Impacting the pipeline through discovery synthesis groups: Cystic fibrosis, HCV, and immunology

Michael Harris, NovoNordisk
Development of PMC friendly approaches to the construction of synthetically challenging cyclopropane motifs

Josh Kaitz, Dupont
Rational design of organic materials for advanced microlithography

Jonrock Kong, Merck
Design and development of catalytic processes for the synthesis of antiviral agents EFdA (MK-8591) and vaniprevir (MK-7009)

Chad Lewis, Pfizer
Asymmetric atropisoinduction

David Marcoux, BMS
Rationally designed, conformationally constrained inverse agonists of ROR?t: Identification of a potent, selective series with biologic-like in vivo efficacy

Tricia May-Dracka, Biogen
Investigation of small molecule inhibitors of PLD for the treatment of ALS

Meredith McGowan, Merck
Discovery and evolution of potent and selective heme-displacing IDO1 inhibitors

Jordan Meier, NCI
New insights into acetylation & oncometabolism from chemoproteomics

Theo Michels, eFfector
Synthesis of bioactive flavagline analogues as inhibitors of cap-dependent translation: Discovery of eFT226

Erik Regalado, Merck
Universal chromatographic methods and fit for purpose workflows in the research and development of new pharmaceuticals

Benjamin Sherry, Merck
Process development in the pharmaceutical industry

Iulia Strambeau, GSK
Convergent synthesis of the NS5B inhibitor GSK8175 enabled by transition metal catalysis

Jenna Terebetski
Want to improve your (bio)performance? Take a closer look at the physical properties

Rubben Torella, Pfizer
Designing for bias: Computational methods to drive rational design of G-protein biased agonists

Joseph Tucker, Pfizer
High-throughput experimentation in flow: From screening to compound production

Steven Wisniewski, Bristol-Myers Squibb
Robust catalytic transformations: Value of mechanistic studies in process chemistry

Robert Wright, Dow
Organic molecules as forensic fuel markers

Ian Young, Genentech
Application of under-utilized transformations to the synthesis of pharmaceutically relevant molecules

2018 Young Investigator’s Symposium

Karla Bravo-Altamirano, Corteva Agriscience
Synthesis and bioactivity of carbohydrate-based macrocyclic picolinamide fungicides.

Alison Brewer, Pfizer
Design, development and scale-up of a homogeneous Chan-Lam coupling

Matthew Campbell, Merck
Herbicidal 2-aryl-1,2,3-triazoles

Benoit Cardinal-David, Abbvie
Flow chemistry: Impact on early process development

Chiol Chung, Genentech
Expedient synthesis of chiral tryptamines via a regioselective indole alkylation

Jamie McCabe Dunn, Merck
Vignettes in process chemistry spanning enabling discovery chemistry to manufacturing route development

Marie Gabrielle-Braun, Genentech
Discovery of GDC-0077: A highly selective inhibitor of PI3K-alpha that induces degradation of mutant-p110 alpha protein

Tom Greshock, Merck
Innovative chemistry enabling drug discovery: Leveraging new frontiers in organic synthesis to improve success rate

David Laitar, Dow
Boron- and copper-based TADF emitters: Synthesis, photochemical characterization and OLED device performance

Ricardo Lira, Pfizer
Preparation and optimization of macrocyclic peptide-like inhibitors for intravenous applications

Sheng Liu, Dow
Design and synthesis of high carbon content polymers via catalytic oxidative cross-coupling reactions for application in advanced manufacture

Michael Luzung, Bristol–Myers Squibb
Discovering innovative and impactful chemistry through external collaborations

Steven M. Mennen, Amgen
Integration of discovery and process development to deliver a high complexity BACE inhibitor

Joseph Pero, GlaxoSmithKline
Discovery of a novel class of TRPV4 antagonists and optimization with respect to LLE, oral PK properties and off-target activity

Angela Puchlopek-Dermenci, Pfizer
Commercial route development of a SMO inhibitor

Aaron Smith, Pfizer
Speed to clinic: The critical role of organic synthesis in medicinal chemistry.

2017 Young Investigator’s Symposium

Scott Bader, Pfizer
Synthesis of active pharmaceutical ingredients (APIs): Difficulties in the synthesis of the parts can be greater than that of the whole

Douglas Behenna, Pfizer
Discovery and early enablement of PF-06747775: A next generation irreversible inhibitor of mutant EGFR for the treatment of NSCLC.

Aaron Burns, Dart Neuroscience
Aldehyde Oxidase Metabolism in Drug Discovery

Vincent Chan, AbbVie
Development of a robust process for Venetoclax

Michael Demartino, GlaxoSmithKline
Next generation RET kinase inhibitor: Improved physicochemical and PK properties enhance local GI tissue distribution

Kevin Hesp, Pfizer
Synthesis of Photoreactive Chemical Probes through Late-Stage Heterocyclic C-H Functionalization of Unmodified Biologically Active Molecules

Xin Linghu, Genentech
Development of a practical synthesis of small molecule intermediate for THIOMAB-antibiotic conjugates (TACs)

Zhijian Liu, Merck
Asymmetric Hydrogen Bonding Catalysis for the Synthesis of Dihydroquinazoline-containing Antiviral, Letermovir

Ana Minatti, Amgen
Fueling the Alzheimer’s BACE1 Race with Genetic Insights and Cyclopropyloxazine BACE1 Inhibitors

Christian Nilewski, eFFECTOR Therapies
Design and synthesis of novel natural product-inspired eIF4A inhibitors

Thomas Pillow, Genentech
New Chemistries for Antibody-Drug Conjugates

Izzat Raheem, Merck
Discovery of 2-pyridinone aminals: A prodrug strategy to advance a second generation of HIV-1 integrase strand transfer inhibitors

Matthew Schiffler, Lilly
mPGES-1 Inhibitors from start to clinic

Eric Simmons, Bristol–Myers Squibb
Discovery, Development and Mechanistic Study of Catalytic Transformations for the Multi-Kilogram Scale Synthesis of Pharmaceutical Intermediates

Emile Velthuisen, GlaxoSmithKline
Design of Highly Potent Allosteric Integrase Inhibitors

Abbas Walji, Merck
New opportunities for synthetic chemistry to enable drug discovery: Discovery of [18F]MK-6240 a novel PET imaging agent for tau pathology

2016 Young Investigator’s Symposium

Robert Aversa, Novartis
ATR inhibitors for cancer: SBDD and mitigation of TDI

Haiming Zhang, Genentech
Practical processes to selective estrogen receptor degrader GDC-0810

Michael Schmidt, Bristol-Myers Squibb
Case studies in process research: Small molecules with big challenges

Hua Xu, Pfizer
Applications of sulfonyl fluorides in drug discovery and chemical biology

Erin P. Keaney, Novartis
Disruption of autophagy in vivo via selective Vps34 inhibitors

Eric C. Hansen, Pfizer
Mining pharmaceutical libraries for new ligands in nickel catalysis

Philip Fontaine, Dow Chemical
Discovery and development of molecular polyolefin catalysts

Hilary S. Eidam, GlaxoSmithKline
RET inhibitors for the treatment of irritable bowel syndrome

Christopher am Ende, Pfizer
Design and application of photoaffinity probes to investigate the mechanism of action of ?-secretase inhibitors and modulators

Joseph R. Martinelli, Eli Lilly
Evolution of a platform for aerobic processes

Malliga R. Iyer, National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Synthetic approaches toward the design of multi-target compounds for the treatment of metabolic disorders and fibrosis

Anna V. Davis, Dow Chemical
Advances in the direct control of polyethylene oxide molecular weight

Mirlinda Biba, Merck
Chromatographic analysis and separation of short RNA oligonucleotides with novel liquid chromatography methods

Dennie S. Welch, AbbVie
Development of a practical asymmetric synthesis of a TRPV1 antagonist

Arjun Raghuraman, Dow Chemical
Sequential DMC/FAB-catalyzed alkoxylation towards high primary hydroxyl, high equivalent weight polyether polyols

Jackie Milne, Amgen
Development of a robust process for a cMet inhibitor

2015 Young Investigator’s Symposium

Gregg Keaney, H3 Biomedicine
Total synthesis of 6-deoxypladienolide D and assessment of splicing inhibitory activity in a mutant SF3B1 cancer cell line

Roy Helmy, Merck
Development and implementation of innovative high-throughput screening and analysis solutions to support discovery and development of active pharmaceutical ingredients in the pharmaceutical industry

Patricia Brieva, L’Oreal
Organic acid applications within the cosmeceutical industry “chemical peels”

Reema Thalji, GlaxoSmithKline
Structure-guided design and optimization of fluoroquinolone-substituted bacterial type IIA DNA topoisomerase inhibitors

Paul LaBeaume, Dow Chemical
Application of synthetic organic chemistry in the design of cationic initiators for next generation photoresists

Kevin Cole, Eli Lilly
Continuous processing: Chemical route development and GMP implementation

Timothy Briggs, Ensemble Therapeutics
DNA-programmed chemistry toward macrocycle libraries for drug discovery

Andrew Vetter, Eastman Chemical
Cobalt catalyzed reductive carbonylation of methanol

Andrew Hejl, Dow Chemical
Designed hybridization – acrylic-epoxy hybrid dispersions for industrial coating applications

Nathan Ide, Pfizer
Development of a commercial manufacturing process for Ibrance® (palbociclib)

Jeffrey Kallemeyn, AbbVie
Approaches to the heterocyclic core of Ilorasertib

Andrew Satterfield, DuPont
Carbonyl containing heterocycles as aromatic isosteres in 4-hydroxyphenylpyruvate dioxygenase (HPPD) herbicides

Antonella Converso, Merck
Discovery of adenosine analog inhibitors of S-adenosylhomocysteine hydrolase

Ke Chen, Bristol-Myers-Squibb
Overcoming steric and electronic obstacles: Development of efficient syntheses of active pharmaceutical ingredients

Martin Schnermann, National Cancer Institute
Near-IR uncaging chemistry: Discovery and applications

Sheng Cui, Amgen
Chiral chemistry for API synthesis

2014 Young Investigator’s Symposium

Nicole Knight, Dow Chemical
Multidisciplinary problem solving in industrial research

Anthony A Estrada, Genentech
Access to potent, selective, efficacious, and highly functionalized pyrimidoaminotropane mTOR inhibitors through the development of a flexible pyrimidine methodology

Christoph W Zapf, Pfizer
Lessons learned from targeting interleukin-2 inducible T cell kinase (ITK) by a covalent approach

Kelly M George, L’Oreal
Development of new skin care cleansing formulations using design of experiment and fast formulation tools

Beth M. Cooper, Dow Chemical
Latex-pigment interactions in paint to reduce environmental impact and improve performance

Rebecca T Ruck, Merck
MK-7655: Surprising synthetic complexity for seemingly straightforward steps

Adrian Ortiz, Bristol-Myers-Squibb
Discovery of an innovative stereoselective synthesis of BMS-986001: A nucleoside reverse transcriptase inhibitor (NRTI) for the treatment of HIV infection

Sébastien Lemaire, Janssen Pharmaceutica
Stereoselective C-glycosylation reactions with arylzinc reagents

Shashank Shekhar, AbbVie
Discovery of novel catalytic technologies in the process development of HCV polymerase inhibitors

Jared L. Piper, Eli Lilly
Process development and synthetic approaches for a CB1 inverse agonist

2013 Young Investigator’s Symposium

Santhosh F Neelamkavil, Merck
Discovery of bridged bicyclic piperidines as GPR119 agonists for the treatment of Type 2 diabetes

Kurt Hirsekorn, Dow Chemical
Selective methane activation and chlorocarbon development for climate friendly refrigerants via free radical chemistries

John S. Schneekloth, National Cancer Institute
Chemical probes of protein sumoylation: Strategies and tactics

David L. Gray, Pfizer
Medicinal chemistry at the blood-brain interface: Challenge and opportunity

Shawn D. Walker, Amgen
Development of new methods for the asymmetric synthesis of small molecule drug candidates

Allyn T. Londregan, Pfizer
Synthetic enablement for drug discovery: A new method for the addition of nucleophiles to pyridine-N-oxides

Owendi Ongayi, Dow Electronic Materials
Development of materials for semiconductor device fabrication

Rami Hannoush, Genentech
Peptides tools for targeting the zymogen form of a caspase

Artis Klapars, Merck
Asymmetric synthesis of complex drug targets

2012 Young Investigator’s Symposium

Michael T. Rudd, Merck
Discovery of vaniprevir (MK-7009) and MK-5172: Macrocyclic HCV NS3/4a protease inhibitors

Stephen M. Lynch, Hoffmann-La Roche
Design and synthesis of novel monoamine triple reuptake inhibitors

Jason S. Tedrow, Amgen
Route selection toward AMG 222: A direct tetrazole addition strategy toward building molecular complexity

Ming Xu, DuPont Crop Protection
Synthesis and crop protection utility of novel fused heterobicyclic isoxazolines

Ed Cleator, Merck
Discovery of an asymmetric synthesis of suvorexant

Lori Krim Gavrin, Pfizer
Adventures in medicinal chemistry: Drug design and probe design

2011 Young Nonacademic Investigators

Vincent Mascitti, Pfizer
Discovery of clinical candidate PF-04971729: An anti-diabetic agent from the structurally unique dioxa-bicyclo[3.2.1]octane class of SGLT2 inhibitors

Lisa A. Marcaurelle, Broad Institute
Diversity-oriented synthesis: From macrocyclesto spirocycles and beyond

Brian C. Shook, Johnson & Johnson
Indenopyrimidines as dual adenosine A2A/A1 antagonists for the treatment of Parkinson’s disease

Xing Dai, Merck
Example of drug discovery program leading to the development of novel reactions

Aaron T. Wright, Pacific Northwest National Laboratory
Identification of proteins relevant to bioenergy and disease pathology by chemical proteome profiling

Spencer D. Dreher, Merck
Collaboration and communication in chemistry

Ted W. Johnson, Pfizer
HIV integrase and the Golden Triangle: Overcoming synthetic challenges to compounds occupying unique chemical space

Martin D. Eastgate, Bristol-Myers Squibb
On the palladium catalyzed oxidation of cyclic dienes

2010 Young Nonacademic Investigators

Vassil I. Elitzin, GlaxoSmithKline
Efficient and practical synthesis of GSK812397, an HIV drug candidate

Qinhua Huang, Pfizer
Synthesis and evaluation of NO donor containing carbonic anhydrase inhibitors

Andrew W. Fraley, Ensemble Discovery
DNA-programmed chemistry approaches to macrocyclic lead compounds

Catherine A Faler, ExxonMobil Chemical Company
Synthesis of pyridyl amine ligands for catalyzed ethylene oligomerization

Robert D. Mazzola, Jr., Merck/Ligand Pharmaceuticals
Design and synthesis of novel ß-secretase (BACE) inhibitors

Hannah Yu, Eli Lilly
Development of an efficient palladium-catalyzed intramolecular carbometalation reaction for the synthesis of a dibenzoxapine-containing tetrasubstituted exocyclic alkene

Fa Liu, National Cancer Institute
Peptide mimetics disrupting protein-protein interactions discovered by post-solid phase modifications

Francis Gosselin, Merck
Asymmetric hydrogenation of unprotected N-H ketoimines

Nidhi Gupta, Biodesign Institute, Arizona State University
Synthetic ligands (synbodies): Syntheticalternatives to antibodies

Matthew M. Bio, Amgen
Practial arene metallation chemistry

2009 Young Investigator’s Symposium

Craig J. Thomas, National Institutes of Health
Bioactive small molecule discovery at the NIH chemical genomics center

David Tellers, Merck
Application of automation to synthetic organic challenges Shawn M. Dirk, Sandia National Laboratories
Development of novel polymeric capacitor dielectric materials

Xianhai Huang, Schering-Plough Research Institute
Total synthesis and SAR development of potent antitumor natural product psymberin/irciniastatin A

Andrew E. Taggi, DuPont Crop Protection
Chemistry at the interface of agriculture and medicine: Pyrazinones as tubulin modulators

Dafydd R. Owen, Pfizer
Enabling the hit to lead process at Pfizer: The value of organic synthesis

M. Uljana Mayer, Pacific Northwest National Laboratory
New probes for proteomics: Synthesis and application to problems in health and bioenergy

Karin M. Balss, Cordis Corporation
Investigation of chemical spatial distribution of drug and polymer in drug-eluting stent coatings

Stefan G. Koenig, Sepracor
Lessons learned: Development of a catalytic asymmetric hydrogenation process

Daniel H. Appella, National Institutes of Health
Molecular designs for peptide nucleic acids in detection and multivalent platforms

Eric Assen B. Kantchev, Forma Therapeutics Singapore
Rational exploration and exploitation of palladacycle diversity: Design and development of the SingaCycle family of NHC-palladacycle cross-coupling catalysts

Oliver Thiel, Amgen
Synthesis and process development of an advanced drug candidate

Jeffrey C. Gildersleeve, National Cancer Institute
Multidimensional carbohydrate microarrays for cancer research

2008 Young Investigator’s Symposium

Yue-Mei Zhang, Johnson & Johnson
Regioselective Pd-catalyzed coupling of halopyrimidines and synthesis of functionalized pyrimidoindole heterocycles

Shane W. Krska, Merck
Harnessing the power of high-throughput experimentation for catalytic reaction development at Merck

Percy H. Carter, Bristol-Myers Squibb
Discovery of potent, selective, and orally bioavailable antagonists of CC Chemokine Receptor 2

Florence Mehlmann, Arkema
Developments of new polymer architectures by controlled radical polymerization

Zhao-Kui Wan, Wyeth Research
Serendipitous synthetic discoveries: A tale of phosphonium and oxybenzotriazole chemistry

Daniel Steiger, General Electric Global Research
Rational design of surfaces with nanometer-sized domains for improved blood compatibility

Kanth V. B. Josyula, Aldrich Chemical Company
Enabling boron-based reagents in chemical synthesis: A story of advancing science through new product development at Aldrich

Brian A. Johns, GlaxoSmithKline
Novel synthetic methods to facilitate the pursuit of antiviral drugs

Erik J. Hembre, Eli Lilly
Discovery of the NK-1 antagonist LY686017

2007 Young Investigator’s Symposium

J. Kent Barbay, Johnson & Johnson
Synthesis and evaluation of small molecule C5a receptor antagonists

Kevin R. Campos, Merck
Enantioselective arylation of N-Boc pyrrolidine

Robert M. Borzilleri, Bristol-Myers Squibb
From cytotoxic agents to targeted therapies: A new era in oncology research

Robert A. Singer, Pfizer
Development of nonproprietary catalysts for the palladium-catalyzed amination reaction

Edmund I. Graziani, Wyeth Research
Synthesis and chemical biology of ILS-920: A novel non-immunosuppressive rapamycin analog with efficacy in multiple animal models of ischemic stroke